Publications by authors named "B R Konety"
Although clinical trials should be accessible to all patients, persistent racial and ethnic disparities in clinical trial enrollment exist. Herein, we examine racial disparities in clinical trial enrollment among prostate cancer patients from a large population-based cohort of oncology practices in the United States. Using CancerLinQ Discovery, we identified men with regional (N1+) and/or metastatic (M1) prostate cancer diagnosed from 2011 to 2023.
View Article and Find Full Text PDFThe purpose of this study was to examine the experiences of discrimination during prostate cancer treatment and assess the association with health-related quality of life (HRQOL) in a cohort of gay and bisexual men (GBM) prostate cancer survivors. This is a cross-sectional analysis of the 24-month follow-up survey from the clinical trial that tested the effectiveness of an online rehabilitation program tailored for GBM prostate cancer survivors in the U.S.
View Article and Find Full Text PDFArticle Synopsis
- This study aimed to enhance understanding of upper tract imaging in patients assessed for hematuria, evaluating imaging rates and effectiveness using a national cohort of insured individuals.
- A total of 466,710 patients were analyzed between 2010 and 2015, with various imaging modalities revealing low detection rates: ultrasound (1%), CT (1.7%), and other methods (2.7%).
- The results suggest that while the diagnostic yield of imaging is higher than expected, overall detection remains low, indicating a potential preference for using ultrasound in initial evaluations based on updated guidelines.
Identifying the best candidate for focal therapy: a comprehensive review.
Prostate Cancer Prostatic Dis
October 2024
Background: Despite the evidence supporting the use of focal therapy (FT) in patients with localized prostate cancer (PCa), considerable variability exists in the patient selection criteria across current studies. This study aims to review the most recent evidence concerning the optimal approach to patient selection for FT in PCa.
Methods: PubMed database was systematically queried for studies reporting patient selection criteria in FT for PCa before December 31, 2023.
Non-muscle-invasive bladder cancer (NMIBC), which is restricted to the mucosa (stage Ta, carcinoma in situ (CIS)) or submucosa (stage T1), comprises 75% of bladder cancer diagnoses. Intravesical bacillus Calmette-Guérin (BCG) therapy is the standard-of-care initial treatment for high-risk NMIBC; however, a significant proportion of patients have BCG-unresponsive disease. While radical cystectomy is a definitive treatment in this setting, not all patients are willing or able to undergo this complex procedure associated with morbidity, mortality, and decreased quality of life.
View Article and Find Full Text PDF